RxDoctor Payments Data

Philip Chiotellis, MD

Cardiovascular Disease · Hyannis, MANPI 1073566675

Payments from drug & device makers

$2,238in general payments, 2019–2025

Across 75 payments — averaging $29.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$788
  • Johnson & Johnson$361
  • E.r. Squibb & Sons, L.L.C.$325
  • Bayer$165
  • Pfizer$165
  • Edwards Lifesciences$77
  • plus $358 from 9 others

What the payments were for

  • Food & beverage$1,42764%
  • Education$241%
  • Other$78835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,238 in reported general payments places this provider in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$735,918
Medicare patients
3,479
Services billed
9,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban550$610,431
EliquisApixaban401$472,466
EntrestoSacubitril/Valsartan61$78,607
MultaqDronedarone Hcl14$31,303
NexlizetBempedoic Acid/Ezetimibe32$20,495
JardianceEmpagliflozin24$17,980
Metoprolol Succinate694$13,758
Atorvastatin Calcium825$12,476
FarxigaDapagliflozin Propanediol14$11,594
Rosuvastatin Calcium278$11,083
Nebivolol Hcl171$10,836
Digoxin290$10,264
Losartan Potassium497$7,556
Lisinopril724$5,538
Ezetimibe73$4,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$361$610,431550 claims
PfizerEliquis$165$472,466401 claims
NovartisEntresto$77$78,60761 claims
Sanofi-aventis U.S. LLCMultaq$42$31,30314 claims
Esperion Therapeutics, Inc.Nexlizet$44$20,49532 claims
AstraZenecaFarxiga$39$11,59414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →